Rachel Sanborn
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer (NCT04364048) | Rachel Sanborn | 2020-06-18 |
Track Rachel Sanborn automatically
Every clearance here is in the API, with alerts when new ones post.